Compare Bristol-Myers Squibb Co (BMY) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Logitech International SA — how do they compare? Bristol-Myers Squibb Co trades at $58.48 (market cap $116.30B), while Logitech International SA trades at $99.31 (market cap $14.53B). The key difference: Bristol-Myers Squibb Co is far larger — about 8× Logitech International SA's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | LOGI | |
|---|---|---|
Market Cap | $116.30B | $14.53B |
Sector | Health | Technology |
52-Week High | $62.37 | $126.69 |
52-Week Low | $42.60 | $85.84 |
Enterprise Value | $152.24B | $12.88B |
Dividend Yield | 4.42% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Logitech (LOGI) trades at $102.22, up 0.26% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a net margin of 14.69% and ROE of 32.78%, while recent quarters show consistent earnings beats. New product launches and a partnership with Call of Duty: Modern Warfare 4 highlight ongoing growth initiatives. Cash flow trends remain positive with 2026 operating cash flow projected at $1.0 billion.
Outlook is cautiously optimistic given mixed analyst ratings but solid fundamentals. Upside exists to the $113 consensus target, though competitive pressures and reliance on consumer spending pose risks. The stock offers value if execution on B2B and AI products drives margin expansion as anticipated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
